Teladoc Health (NYSE:TDOC – Get Free Report) will likely be issuing its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $625.6640 million for the quarter. Teladoc Health has set its Q3 2025 guidance at -0.350–0.200 EPS. FY 2025 guidance at -1.350–1.000 EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.
Teladoc Health (NYSE:TDOC – Get Free Report) last posted its earnings results on Tuesday, July 29th. The health services provider reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.08. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. The firm had revenue of $631.90 million during the quarter, compared to analysts’ expectations of $621.91 million. During the same period last year, the company posted ($0.38) EPS. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Teladoc Health Price Performance
Shares of NYSE TDOC opened at $8.66 on Wednesday. Teladoc Health has a 1 year low of $6.35 and a 1 year high of $15.21. The stock has a market capitalization of $1.53 billion, a P/E ratio of -7.28 and a beta of 1.90. The company’s 50-day moving average is $8.03 and its 200 day moving average is $7.64. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.67 and a quick ratio of 2.58.
Institutional Investors Weigh In On Teladoc Health
Wall Street Analysts Forecast Growth
Several research firms have weighed in on TDOC. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, October 8th. Evercore ISI lifted their price target on Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research report on Wednesday, October 8th. Zacks Research upgraded Teladoc Health from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Mizuho initiated coverage on Teladoc Health in a research report on Friday, July 25th. They set a “neutral” rating and a $10.00 price objective for the company. Finally, Citigroup upped their target price on shares of Teladoc Health from $9.50 to $10.50 and gave the stock a “neutral” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.97.
Get Our Latest Report on Teladoc Health
About Teladoc Health
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Featured Articles
- Five stocks we like better than Teladoc Health
- P/E Ratio Calculation: How to Assess Stocks
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- How to Use the MarketBeat Dividend Calculator
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
- Stock Market Upgrades: What Are They?
- Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.